Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Phase 3

Completed

Conditions: Lymphoma
Graft Versus Host Disease

First Posted Date: 2003-12-02

Last Posted Date: 2015-07-20

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 50

Registration Number: NCT00003414

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Phase 3

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2003-11-25

Last Posted Date: 2009-02-09

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 207

Registration Number: NCT00002989

Locations: 🇮🇹
Ospedale San Eugenio, Rome, Italy
🇧🇪
Institut Jules Bordet, Brussels (Bruxelles), Belgium
🇩🇪
Eberhard Karls Universitaet, Tuebingen, Germany

and more 6 locations

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Melanoma (Skin)

First Posted Date: 2003-11-25

Last Posted Date: 2020-06-30

Lead Sponsor: Louisiana State University Health Sciences Center Shreveport

Target Recruit Count: 6

Registration Number: NCT00003060

Locations: 🇺🇸
Louisiana State University School of Medicine, Shreveport, Louisiana, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Withdrawn

Conditions: Leukemia

First Posted Date: 2003-11-24

Last Posted Date: 2012-11-19

Lead Sponsor: Columbia University

Registration Number: NCT00002761

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: idarubicin
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-11-24

Last Posted Date: 2013-08-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 2078

Registration Number: NCT00002812

Locations: 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 32 locations

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2013-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00072319

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-11-06

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 43

Registration Number: NCT00072007

Locations: 🇨🇭
Hopital des Cadolles, Neuchatel, Neuchatel, Switzerland
🇨🇭
Spitaeler Chur AG, Chur, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 8 locations

Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

Phase 2

Terminated

Conditions: Sarcoma

Interventions: Biological: dactinomycin
Drug: cyclophosphamide
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Procedure: Conventional Surgery
Biological: MESNA (mercaptoethane sulfonate)
Biological: Filgrastim

First Posted Date: 2003-11-06

Last Posted Date: 2014-09-30

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 7

Registration Number: NCT00072280

Locations: 🇺🇸
Kosair Children's Hospital, Louisville, Kentucky, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Spectrum Health Hospital - Butterworth Campus, Grand Rapids, Michigan, United States

and more 71 locations

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Phase 1

Completed

Conditions: Brain Tumors
Central Nervous System Tumors
Neuroblastoma
Sarcoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: thiotepa
Drug: vincristine sulfate
Procedure: conventional surgery
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-11-06

Last Posted Date: 2014-03-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 94

Registration Number: NCT00003141

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

and more 68 locations

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Carcinoma
Primary Peritoneal Carcinoma
Stage IV Ovarian Cancer

Interventions: Biological: Bevacizumab
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis

First Posted Date: 2003-11-05

Last Posted Date: 2015-05-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00072566

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy